Key result
In high-risk Kawasaki disease patients, the median serum tenascin-C level before treatment was higher in non-responders to steroid combination therapy compared to responders.
Why the study?
To evaluate prospectively whether serum tenascin-C can predict resistance to initial treatment in high-risk Kawasaki disease patients, following retrospective findings linking it to IVIG resistance and coronary artery lesions.
Does baseline serum tenascin-C level predict resistance to initial treatment in patients with Kawasaki disease?
Cohort (n=181)
Yes
Does baseline serum tenascin-C level predict resistance to initial treatment in patients with Kawasaki disease?
Serum tenascin-C may serve as a useful biomarker to predict resistance to steroid combination therapy in high-risk patients with Kawasaki disease.
Answers are grounded in this paper and cite their sources.
Serum TN-C may aid early risk stratification in KD; extends retrospective observations but remains hypothesis-generating pending larger validation.
Background Tenascin-C (TN-C) is an extracellular matrix glycoprotein related to tissue inflammation. Our previous retrospective study conducted in 2016 revealed that the serum TN-C level was higher in patients with Kawasaki disease (KD) who were resistant to intravenous immunoglobulin (IVIG) and developed coronary artery lesions (CALs). The present study is a prospective cohort study to assess if the serum level of TN-C could be used as a novel biomarker to predict the risk of resistance to initial treatment for high-risk patients. Methods A total of 380 KD patients were registered and provided serum samples for TN-C measurement before commencing their initial treatment. Patients who did not meet the inclusion criteria were excluded from analysis; of the 181 remaining subjects, there were 144 low-risk patients (Kobayashi score: ≤4 points) and 37 high-risk patients (Kobayashi score: ≥5 points). The initial treatments for low-risk patients and high-risk patients were conventional therapy (IVIG with aspirin) and prednisolone combination therapy, respectively. The patient clinical and laboratory data, including the serum TN-C level, were compared between responders and non-responders to initial treatment. Results In the low-risk patients, there was no significant difference in the median levels of serum TN-C between responders and non-responders to initial therapy. However, in the high-risk patients, the median serum TN-C level in non-responders was significantly higher than that in responders (175.8 ng/ml vs 117.6 ng/ml). Conclusions Serum TN-C could be a biomarker for predicting the risk of high-risk patients being non-responsive to steroid combination therapy. Trial registration: This study was a prospective cohort study. It had been performed in accordance with the Declaration of Helsinki and had been approved by the ethics committee in each institute.
No takes yet. Share an insight, caveat, or question.
Yoshikane et al. (2020) conducted a cohort in Kawasaki disease (n=181). Serum tenascin-C vs. Responders to initial therapy was evaluated on Median serum tenascin-C level before initial treatment in high-risk patients (non-responders vs responders) (p=0.037). In high-risk Kawasaki disease patients, the median serum tenascin-C level before treatment was higher in non-responders to steroid combination therapy compared to responders.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: